-
#CDK12-altered#ProstateCancer: clinical features and therapeutic outcomes to standard systemic therapies, PARP, and PD1 inhibitors presented by Emmanuel Antonarakis, MB BCh#ESMO19 coverage by@zklaassen_md@GACancerCenter on UroToday. http://bit.ly/2nGEV30@myESMOpic.twitter.com/620BDSwiD1
-
EV-103: Enfortumab Vedotin plus Pembrolizumab
#ESMO19: Andrew Krivoshik, MD of@AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO.#ESMO2019 http://dlvr.it/RPJNPX pic.twitter.com/s4hMZhiQFx
-
Efficacy & biomarker analysis of pts with adv. RCC with sarcomatoid histology: subgroup analysis from
#JAVELIN renal 101 presentations by@DrChoueiri@DanaFarber.#ESMO19 coverage by@mikelattanzi@sloan_kettering on UroToday > http://bit.ly/2nU1LEq .@myESMO@pfizer@Merckpic.twitter.com/Vlxdc1QlFg
-
Patient-reported outcomes from
#TITAN in patients with mCSPC discussion by@neerajaiims@huntsmancancer. Written coverage by@zklaassen_md@GACancerCenter on UroToday > http://bit.ly/2mpsR6f@myESMO@JNJNews#ESMO19 pic.twitter.com/BkEoY8sBIw
-
VIDEO: ISOPP 2019 reviews ESMO: data highlights w/
@Dharmisha from@royalmarsdenNHS: http://ow.ly/2Dac30pSJmz@VJOncology@ISOPPorg@BOPACommittee#ISOPP2019#BOPA19#ESMO19#OncoPharm#Melanoma#Sarcoma -
#GALAHAD study of Niraparib in patients with#mCRPC and biallelic DNA-repair gene defects. A pre-specified interim analysis discussion by Mattew Smith, MD, PhD.@harvardmed#ESMO19 coverage by@jberchuck@DanaFarber on UroToday. http://bit.ly/2mEqpZO@myESMO@MassGeneralNewspic.twitter.com/s8Pyos6lEq
-
.
@genentech atezolizumab + bevacizumab Increased OS & PFS in Unresectable Hepatocellular Carcinoma (HCC) [Oct 21, 2019] http://ow.ly/mLgi30pKRxc#hpbcsm#ImmunoOnc IMbrave150#NCT03434379 HT@GIcancerDoc noted#ESMO19 Video http://ow.ly/9iS730pKRxPPrikaži ovu nit -
Incyte Announces Positive Updated Results from FIGHT-202 Phase 2 Trial of Pemigatinib FGFR inhibitor in Previously Treated, Advanced Cholangiocarcinoma [Sep 27, 2019]
@Incyte http://ow.ly/TK1f30pE6cD#hpbcsm#PrecisionMedicine#NCT02924376#ESMO19 Abstract#LBA40 HT@agrotheyPrikaži ovu nit -
MT
@pashtoonkasi [Sep 27, 2019] Number of actionable targets in this target-rich disease are increasing with encouraging results.#ESMO19#PrecisionMedicine#hpbcsmpic.twitter.com/F6yGK2mmcZ
Prikaži ovu nit -
MT
@agrothey [Sep 27, 2019] Pemigatinib in intrahepatic cholangio ca with FGFR fusions/ rearrangements.#ESMO19 https://twitter.com/agrothey/status/1177572609829036032?s=20 …#PrecisionMedicine#hpbcsmpic.twitter.com/Y8PIUeYLmj
Prikaži ovu nit -
Setting up genomic tumor boards – What can be done and what needs to be done discussion by Scott Tomlins, MD, PhD
@UMich.#ESMO19 Written coverage by@aloktewar@DanaFarber on UroToday. http://bit.ly/2mX3HMC@myESMO -
#ESMO19 Invited discussant@Ecastromarcos@CNIO_Cancer thoughts on#GALAHAD,#CDK12-altered#ProstateCancer, preliminary results from#TRITON2, and#HRRm in tumor tissue from men with mCRPC screened for#PROfound Written coverage by@jberchuck@DanaFarber. http://bit.ly/2mEZuwY pic.twitter.com/dUNKJZ3OI5
-
Diagnosis, management, and burden of renal cell carcinomas: results from a global patient survey in 43 countries discussion by
@RachelGiles6@UMCU_Intl.#ESMO19 Written coverage by@zklaassen_md@GACancerCenter on UroToday > http://bit.ly/2nw8HYL@myESMO@kidneycanpic.twitter.com/VQkm212VHp
-
VIDEO: Prof. Siefker-Radtke on the EV-103 trial in bladder cancer w/ Arlene Siefker-Radtke of
@MDAndersonNews: http://ow.ly/oV0k30pXvIS@myESMO@cancernurseEU#ESMO19#EONS12#BlcSM#CTSM#ClinOnc -
Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumor tissue from >4000 men with
#mCRPC screened for#PROfound, discussion by@jodebon@ICR_London at#ESMO19. Written coverage by@jberchuck@DanaFarber > http://bit.ly/2oSe1G2@myesmopic.twitter.com/3sxUQHen8v
-
VIDEO: Predicting resistance to targeted therapies in melanoma w/ Christian Blank from
@NKI_nl: http://ow.ly/LjPz30pXw46@myESMO@cancernurseEU#ESMO19#EONS12#CTSM#ClinOnc#Melanoma#Melsm -
ENTRATA Study: How does it affect clinicians today?
#ESMO19: Chung-Han Lee, MD@ChungHanLee3 of@sloan_kettering answers how it affects clinicians and what is to come in kidney cancer. _______ Data shared today in oral presentation at ESMO Congress 2019… http://dlvr.it/RP1Hqd pic.twitter.com/XXXz48075R
-
An adaptive biomarker-directed platform study with Durvalumab in combination w/ targeted therapies in metastatic urothelial cancer
#BISCAY presentation by@tompowles1@QMBCI.#ESMO19 coverage by@MikeLattanzi@sloan_kettering on UroToday. http://bit.ly/2nxjzW1@myESMOpic.twitter.com/plUGx5jfbo
-
#ESMO19 Invited Discussant Christian Kollmannsberger, MD@BCCancer discussion of germ cell tumor studies and RCC disease management methods. Written coverage by@jberchuck@DanaFarber on UroToday. http://bit.ly/2n4Of0I@myESMOpic.twitter.com/eKY0UExAxy
-
VIDEO: REACH safety data: avelumab plus RT-cetuximab in LA SCCHN w/ Jean Bourhis from
@CHUVLausanne: http://ow.ly/hRuE30pYchU@myESMO@cancernurseEU#ESMO19#ClinicalTrial#ClinOnc#SkinCancer#skcSM
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.